MedTrace Logo

Genetic Abnormalities and Biological Changes of Panic Disorder Patients After Pharmacotherapy

NCT00515996 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2007-08-14

No results posted yet for this study

Summary

We plan to examine genetic polymorphism of catechol-O-methyltransferase in panic disorder and neurobiological changes of panic disorder patients after 12 weeks of pharmacotherapy with paroxetine. We plan to include 40 panic disorder patients and 40 normal control subjects in this study for 3 years.

Conditions

  • Panic Disorder

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Bum-Hee Yu, M.D. & Ph.D. · Samsung Medical Center, Sungkyunkwan University School of Medicine

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-01-31
Completion
2008-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00515996 on ClinicalTrials.gov